Asymchem(002821)
Search documents
凯莱英盘中跌逾6%,股价创逾3个月新低,Q3净利同比降13.46%。
Xin Lang Cai Jing· 2025-10-31 06:53
Group 1 - The core point of the article is that Kailaiying's stock price fell over 6% during trading, reaching a new low not seen in over three months, and the company's net profit for Q3 decreased by 13.46% year-on-year [1] Group 2 - The decline in net profit indicates potential challenges the company is facing in maintaining profitability [1] - The significant drop in stock price may reflect investor concerns regarding the company's financial performance and future outlook [1] - The three-month low in stock price could impact investor sentiment and market perception of the company's stability [1]
机构风向标 | 凯莱英(002821)2025年三季度已披露持股减少机构超10家
Xin Lang Cai Jing· 2025-10-31 02:56
Group 1 - Key Point 1: As of October 30, 2025, a total of 42 institutional investors disclosed holdings in Kailaiying A-shares, with a total holding of 174 million shares, accounting for 48.14% of Kailaiying's total share capital [1] - Key Point 2: The top ten institutional investors collectively hold 46.97% of Kailaiying's shares, with a decrease of 1.46 percentage points compared to the previous quarter [1] Group 2 - Key Point 1: In the current period, 10 public funds increased their holdings, with a total increase ratio of 0.15%, including major funds like Morgan Stanley Health Industry Mixed A and Southern Medical Health Flexible Allocation Mixed A [2] - Key Point 2: 14 public funds decreased their holdings, with a total decrease ratio of 0.56%, including funds such as Huabao CSI Medical ETF and Southern CSI 500 ETF [2] - Key Point 3: 12 new public funds were disclosed in the current period, including Guangfa Shengjin Mixed A and Huatai-PB Medical Health A [2] - Key Point 4: 493 public funds were not disclosed in the current period, including funds like Fortune Tianhui Growth Mixed (LOF) A/B and Southern CSI 500 ETF [2] Group 3 - Key Point 1: One foreign fund increased its holdings, specifically Hong Kong Central Clearing Limited, with an increase ratio of 0.17% [3] - Key Point 2: One new foreign institution was disclosed, namely ASYMCHEM LABORATORIES, INCORPORATED [3] - Key Point 3: ASYMCHEM LABORATORIES, INCORPORATED was not disclosed in the previous quarter [3]
凯莱英股价跌5.2%,国投瑞银基金旗下1只基金重仓,持有4.07万股浮亏损失21.69万元
Xin Lang Cai Jing· 2025-10-31 01:56
Group 1 - The core point of the news is that Kailaiying's stock price dropped by 5.2% to 97.20 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.84%, resulting in a total market capitalization of 35.05 billion CNY [1] - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. is located in Tianjin Economic and Technological Development Zone and was established on October 7, 1998, with its listing date on November 18, 2016 [1] - The company's main business involves providing CMO pharmaceutical outsourcing services, with revenue composition being 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - From the perspective of fund holdings, Guotou Ruijin Fund has one fund heavily invested in Kailaiying, specifically the Guotou Ruijin Healthcare Mixed A Fund (000523), which held 40,700 shares in the third quarter, accounting for 3.21% of the fund's net value, ranking as the seventh largest holding [2] - The Guotou Ruijin Healthcare Mixed A Fund (000523) was established on February 25, 2014, with a latest scale of 129 million CNY, and has achieved a year-to-date return of 33.75%, ranking 2696 out of 8154 in its category [2] - The fund manager, Liu Zexu, has been in position for 2 years and 51 days, with a total asset scale of 243 million CNY, achieving a best return of 29.7% and a worst return of 19.71% during his tenure [2]
凯莱英(06821.HK)获Norges Bank增持13.22万股


Ge Long Hui A P P· 2025-10-30 23:41
Core Insights - Norges Bank increased its stake in Kairong (06821.HK) by purchasing 132,200 shares at an average price of HKD 89.7083 per share, totaling approximately HKD 11.8594 million [1] - Following this transaction, Norges Bank's total shareholding in Kairong rose to 3.3734 million shares, increasing its ownership percentage from 11.75% to 12.24% [1] Summary by Categories - **Transaction Details** - Norges Bank acquired 132,200 shares at an average price of HKD 89.7083 per share [1] - The total investment amounted to approximately HKD 11.8594 million [1] - **Shareholding Changes** - Post-transaction, Norges Bank's total shares held in Kairong reached 3.3734 million [1] - The ownership percentage increased from 11.75% to 12.24% [1]
凯莱英(002821.SZ)发布前三季度业绩,归母净利润8亿元,增长12.66%


智通财经网· 2025-10-30 11:08
智通财经APP讯,凯莱英(002821.SZ)发布2025年三季度报告,该公司前三季度营业收入为46.3亿元,同 比增长11.82%。归属于上市公司股东的净利润为8亿元,同比增长12.66%。归属于上市公司股东的扣除 非经常性损益的净利润为7.28亿元,同比增长9.74%。基本每股收益为2.18元。 ...
凯莱英(06821)前三季度归母净利润8亿元 同比增加12.66%
智通财经网· 2025-10-30 11:08
Core Viewpoint - The company reported a revenue of 4.63 billion RMB for the first three quarters of 2025, reflecting a year-on-year increase of 11.82%, and a net profit attributable to shareholders of 800 million RMB, up 12.66% [1] Revenue Breakdown - The revenue from small molecule business remained stable, while emerging business revenue grew by 71.87% year-on-year, and revenue from large molecule chemistry increased by over 150% [1] - Revenue from large pharmaceutical companies was 2.053 billion RMB, a year-on-year increase of 1.98%, while revenue from small and medium-sized pharmaceutical companies reached 2.577 billion RMB, up 21.14% [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an overall revenue growth of 13%-15% for the year [1]
Norges Bank增持凯莱英13.22万股 每股作价约89.71港元


Zhi Tong Cai Jing· 2025-10-30 11:04
Group 1 - Norges Bank increased its stake in Kelaiying (002821)(06821) by 132,200 shares at a price of HKD 89.7083 per share, totaling approximately HKD 11.8594 million [1] - After the increase, Norges Bank's total shareholding in Kelaiying reached 3.3734 million shares, representing a 12.24% ownership stake [1]
Norges Bank增持凯莱英(06821)13.22万股 每股作价约89.71港元


智通财经网· 2025-10-30 11:03
Core Insights - Norges Bank increased its stake in Kairong (06821) by acquiring 132,200 shares at a price of HKD 89.7083 per share, totaling approximately HKD 11.8594 million [1] - Following this acquisition, Norges Bank's total shareholding in Kairong reached 3.3734 million shares, representing a 12.24% ownership stake [1] Company Summary - Norges Bank's recent purchase indicates a strategic move to enhance its investment in Kairong, reflecting confidence in the company's future performance [1] - The increase in shareholding percentage to 12.24% suggests a significant commitment to Kairong, potentially influencing market perception and investor sentiment [1]
凯莱英(06821.HK)第三季度净利润约为1.83亿元 同比下降13.46%


Ge Long Hui· 2025-10-30 10:48
格隆汇10月30日丨凯莱英(06821.HK)公布2025年第三季度报告。营收约为人民币14.42亿元,同比下降 0.09%。净利润约为1.83亿元,同比下降13.46%。基本每股收益为0.5元。 前三季度营收约为46.3亿元,同比上升11.82%。净利润约为8亿元,同比上升12.66%。 ...
凯莱英(06821) - 2025年第三季度报告
2025-10-30 10:32
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其 準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團(天津)股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:6821) 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文,僅供參閱。 承董事會命 凱萊英醫藥集團(天津)股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津,二零二五年十月三十日 於本公告日期,本公司董事會由董事長兼執行董事 Hao Hong 博士,執行董事楊蕊女士 、張達先生及洪亮先生,非執行董事 Ye Song 博士及張婷女士,以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 凯莱英医药集团(天津)股份有限公司 2025 年第三季度报告 证券代码:002821 证券简称:凯莱英 公告编 ...